Literature DB >> 24114901

Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping.

Wei Tai, Sheryl L Gong, Shirley M Tsunoda, Howard E Greenberg, J Christopher Gorski, Scott R Penzak, S Aubrey Stoch, Joseph D Ma.   

Abstract

BACKGROUND: Midazolam apparent oral clearance (CLORAL) is used to estimate intestinal and hepatic cytochrome P450 (CYP) 3A activity. A limited sampling approach was performed to access a midazolam partial area under the concentration time curve (AUC) to estimate CLORAL.
METHODS: Midazolam plasma concentrations from healthy adults were obtained during CYP3A baseline (n=116), inhibition (n=75), and induction or activation (n=66) from seven published studies. Observed CLORAL and partial AUCs of AUC0-2, AUC0-4, AUC0-6, AUC1-2, AUC1-4, AUC2-4, and AUC2-6 were determined by noncompartmental analysis. Subject data were randomly divided into a training set and a validation set. Linear regression equations, derived from partial AUCs, were developed from training set data. Predicted CLORAL was determined from these equations from validation set data. Preset criterion was a coefficient of determination (r2) greater than or equal to 0.9. Bias and precision were evaluated by relative percent mean prediction error (%MPE) and relative percent mean absolute error (%MAE).
RESULTS: During CYP3A baseline conditions, all of the evaluated CLORAL equations had unacceptable r2 (range: 0.34-0.86). During CYP3A inhibition, all of the evaluated CLORAL equations had unacceptable %MAE. Acceptable r2, %MPE, and %MAE were observed during CYP3A induction/activation with AUC0-4 (r2=0.99, %MPE=3.9, %MAE=12.5) and AUC1-4 (r2=0.99, %MPE=6%, %MAE=11.1%). The same equations also predicted the extent of CYP3A induction as a lack of equivalence was observed with AUC0-4 and AUC1-4.
CONCLUSIONS: Midazolam partial AUCs were unable to estimate CYP3A activity during the evaluated baseline and inhibitory conditions. Midazolam CLORAL utilizing a partial AUC0-4 and AUC1-4 was able to estimate CYP3A induction with rifampin and Ginkgo biloba extract.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24114901     DOI: 10.1515/dmdi-2013-0040

Source DB:  PubMed          Journal:  Drug Metabol Drug Interact        ISSN: 0792-5077


  4 in total

1.  Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping.

Authors:  Joanna C Masters; Denise M Harano; Howard E Greenberg; Shirley M Tsunoda; In-Jin Jang; Joseph D Ma
Journal:  Ther Drug Monit       Date:  2015-02       Impact factor: 3.681

2.  Evaluation of Omeprazole Limited Sampling Strategies to Estimate Constitutive Cytochrome P450 2C19 Activity in Healthy Adults.

Authors:  Swan Lin; Mina Nikanjam; Edmund V Capparelli; Alessandro Allegrini; Daniele Pavone; Dong-Seok Yim; Muhammad M Hammami; Joseph S Bertino; Anne N Nafziger; Yoo-Sin Park; Ju-Seop Kang; Ophelia Q Yin; Joseph D Ma
Journal:  Ther Drug Monit       Date:  2018-12       Impact factor: 3.681

3.  A Systematic Review of Drug Metabolism Studies of Plants With Anticancer Properties: Approaches Applied and Limitations.

Authors:  Artitaya Thiengsusuk; Kanyarat Boonprasert; Kesara Na-Bangchang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-04       Impact factor: 2.441

4.  Validation of a 3-h Sampling Interval to Assess Variability in Cytochrome P450 3A Phenotype and the Impact of Induction and Mechanism-Based Inhibition Using Midazolam as a Probe Substrate.

Authors:  Madelé van Dyk; Asha J Kapetas; Ashley M Hopkins; A David Rodrigues; Manoli Vourvahis; Michael J Sorich; Andrew Rowland
Journal:  Front Pharmacol       Date:  2019-09-27       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.